Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on NextCure. The associated price target is $20.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Emily Bodnar’s rating is based on NextCure’s promising advancements in their clinical trials, particularly with their novel antibody-drug conjugates (ADCs) SIM0505 and LNCB74. The ongoing Phase 1 dose-escalation trials for these ADCs have shown encouraging preliminary results, with SIM0505 demonstrating favorable safety and early signs of efficacy in patients with advanced ovarian, lung, and renal cancers. The trials are progressing well, with dose escalation continuing in both the US and China, which is expected to accelerate the identification of the recommended Phase 2 dose (RP2D) and reduce development costs.
Additionally, NextCure’s strategic partnerships and recent amendments to their trials, such as the FDA’s acceptance of higher dose escalation cohorts for LNCB74, further strengthen the company’s position. The anticipated proof-of-concept data readouts in the first half of 2026 are expected to provide more insights into the potential of these treatments. These factors collectively contribute to Emily Bodnar’s Buy rating for NextCure, reflecting optimism about the company’s future prospects and its innovative approach to cancer treatment.
According to TipRanks, Bodnar is a 3-star analyst with an average return of 2.6% and a 35.33% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Olema Pharmaceuticals, and Atossa Therapeutics.
In another report released on November 7, Ladenburg Thalmann & Co. also upgraded the stock to a Buy with a $18.00 price target.